An observational study in Adnexal Mass, Germline BRCA1 Gene Mutation and Germline BRCA2 Gene Mutation, sponsored by Aspira Women's Health. Terminated at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-26.
Sponsored by Aspira Women's Health · Observational
The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.
2,695 studies on the registry are indexed under Ovarian Neoplasms; 727 are open to participants now.
This study's enrollment of 215 is close to the median of 200 across 527 observational studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →Aspira Women's Health is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Women with or without a pelvic mass.
Key inclusion criteria:
Cohort A specific inclusion criteria:
Cohort B specific inclusion criteria:
Cohort C specific inclusion criteria:
Exclusion Criteria:
Women with a pelvic mass, symptomatic or asymptomatic.
Other: OVA360
Women diagnosed with a pelvis mass undergoing genetic testing through our commercial offering.
Other: OVA360
Subject must not have an identifiable adnexal mass and may, or may not, have a family history or a known familial genetic abnormality (germ line or identified in family cancer i.e. somatic DNA mutation) associated with ovarian cancer.
Other: OVA360
Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection
OVA360
Identify the molecular key driver of Ovarian cancer and develop a diagnostic test for early Ovarian cancer detection
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aspira Women's Health